Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bone BiologicsBBLG -0.93%30 14-Day RSI is 28.53 as of Jul. 25, 2026. GuruFocus rates BBLG with a GF Score™ of 30/100. Among 1,424 Biotechnology companies, Bone Biologics ranks better than 94.94% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-25), Bone Biologics's 14-Day RSI is 28.53.
The industry rank for Bone Biologics's 14-Day RSI or its related term are showing as below:
BBLG's 14-Day RSI is ranked better than 94.94% of 1424
companies
in the Biotechnology industry
Industry Median: 45.5
vs BBLG: 28.53
Bone Biologics (NAS:BBLG) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Bone Biologics 14-Day RSI Related Terms
BBLG vs VRAX, PKTX, OGEN: 14-Day RSI Comparison
For the Biotechnology subindustry, Bone Biologics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bone Biologics 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bone Biologics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Bone Biologics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bone Biologics (BBLG) has a 14-Day RSI of 28.53 as of Jul. 25, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Bone Biologics and its competitors. According to the industry distribution chart, Bone Biologics ranks #72 out of 1424 companies in the Biotechnology industry, placing it in the top 5.1%.
Is Bone Biologics' 14-Day RSI too high?
Bone Biologics' current 14-Day RSI is 28.53. The Biotechnology industry median 14-Day RSI is 45.50. Bone Biologics' value of 28.53 is 37.3% below this industry median. Based on the distribution chart, Bone Biologics ranks #72 out of 1424 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bone Biologics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Bone Biologics' 14-Day RSI compare to VRAX and PKTX?
According to the Biotechnology industry distribution chart, Bone Biologics ranks #72 out of 1424 companies for 14-Day RSI. This places Bone Biologics in the top 5% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 45.50. Bone Biologics' value of 28.53 is 37.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 45.50, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bone Biologics's current 14-Day RSI of 28.53 is 37.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Bone Biologics and its competitors. For the Biotechnology industry, the median 14-Day RSI is 45.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bone Biologics's current 14-Day RSI is 28.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bone Biologics stock overvalued right now?
Bone Biologics (BBLG) has a current 14-Day RSI of 28.53. The current 14-Day RSI is 28.53 and 37.3% below the Biotechnology industry median of 45.50. Bone Biologics' overall GF Score™ is 30/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Bone Biologics (BBLG), the current 14-Day RSI is 28.53 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
30GF Score
Get the complete analysis for BBLG
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBLG has been successfully added to your 
